Cheng Lai

Chang Gung Memorial Hospital — Taiwan

Biochemistry, Genetics and Molecular Biology · Life Sciences

3h-index17citations11works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(5), RNA Interference and Gene Delivery(3), Histone Deacetylase Inhibitors Research(2), Circular RNAs in diseases(2), Peptidase Inhibition and Analysis(2)

Publications11 total

IDDF2018-ABS-0152 The preoperative cea can be an independent predictive factor for colorectal cancer patients after curative resection in long-term outcome
Clinical Gastroenterology·2018Open Access
Abstract 1229: RNAi-based β-catenin inhibition in combination with MEK inhibition promotes synergistic anti-tumor efficacy and overcomes resistance with MEK inhibition promotes synergistic anti-tumor efficacy and overcomes resistance
Cancer Research·2017
RNAi-mediated beta-catenin inhibition to promote T-cell infiltration and antitumor activity in combination with immune checkpoint blockade.
Journal of Clinical Oncology·2017· 1 cited
Abstract 3827: Preclinical characterization of DCR-BCAT as a component of combination therapy
Cancer Research·2016· 1 cited
Abstract 2925: Anti-tumor activity of a MYC-targeting dicer substrate siRNA in combination with BRD4/CDK7 inhibitors
Cancer Research·2016· 6 cited
Abstract B20: EnCore-LNP mediated tumor delivery of MYC and CTNNB1 Dicer Substrate RNAs (DsiRNAs)
Molecular Cancer Research·2015· 3 cited
Abstract 3536: Targeting β-catenin with a Dicer-substrate siRNA (DsiRNA) in a sleeping beauty transposon-driven murine hepatoblastoma model
Cancer Research·2015
Abstract 3533: Systemic delivery of CTNNB1 Dicer-substrate siRNAs (DsiRNAs) leads to efficient oncogene silencing in diverse tumor types of extra hepatic origin
Cancer Research·2015· 1 cited
O011 IL-17 receptor adaptor Act1/CIKS plays an evolutionarily conserved role in antiviral signalling
Cytokine·2012
A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer.
Journal of Clinical Oncology·2012· 5 cited
CUDC-101, a synthetic and potent HDAC, EGFR and Her2 inhibitor, effectively inhibits proliferation of cancer cell lines
2007

Frequent Co-authors

Shanthi Ganesh(7), Weimin Wang(7), Hank Dudek(7), Marc Abrams(7), Serena Shui(5), Girish R. Chopda(5), Martin L. Koser(5), Wendy A. Cyr(5), Robert Brown(4), Dongyu Chen(3), Bo Ying(3), Bob D. Brown(3), Edmond Chipumuro(2), Zakir Siddiquee(2), Anee Shah(2), Bo Young Kim(2), Rokhand Arvan(2), Kevin P. Craig(2), Purva Pandya(1), Rachel Storr(1)